Tempo Therapeutics, Backed by Johnson & Johnson, Initiates First-in-Human Trial of Regenerative Scaffold TT101
Johnson & Johnson
Medical Device R&D and Manufacturer
Tempo Therapeutics
Developer of Synthetic Biomaterials
Pioneer in Medical Device Media Reports
Share Professional Medical Device Knowledge
Tempo Therapeutics is developing TT101 for soft tissue regeneration and the repair of complex surgical sites exposing bone, tendon, or fascia. The company received funding from Johnson & Johnson’s venture capital arm to support the trial of its surgical scaffold product.Tempo Therapeutics has begun the first human trial of its tissue regeneration product TT101 for patients undergoing surgical resection.
TT101 is an integrated scaffold with the potential for soft tissue regeneration. This study aims to evaluate the safety of TT101 and collect data on the product's ability to "regenerate large amounts of surgically excised tissue."
TT101 was developed using Microsphere Annealing Particle (MAP) technology, which repurposes hydrogel polymer components into an ultra-porous, flowable scaffold form. This technology is expected to allow immediate tissue growth and integration while avoiding foreign body reactions that cause inflammation and scar formation.
Tempo Therapeutics, Inc. noted that in preclinical animal studies on soft tissue repair, TT101 has "demonstrated non-immunogenicity and regenerative tissue response." The U.S.-based company is developing TT101 for soft tissue regeneration and repair in complex surgical sites exposing bone, tendon, or fascia.
This open-label randomized trial will enroll cancer patients with basal cell carcinoma or squamous cell carcinoma who have undergone surgical resection. TT101 will be applied to these acute surgical tumor resection sites on the skin post-surgery.According to Tempo, TT1010 may improve healing outcomes and reduce the need for secondary interventions, particularly in patients undergoing immunosuppressive therapy.
Tempo Therapeutics is a biomaterials innovation company focused on leveraging the cutting-edge Microscopic Pore Material (MAP) technology platform.On March 19 this year, the company successfully secured $12 million in Series A financing, jointly led by renowned investment firm Galaxy-Sirius Partners and Johnson & Johnson's venture capital division.
The founding team of Tempo Therapeutics has extensive experience. In 2014, Professor Donald Griffin from the University of California, Los Angeles, joined hands with Dr. Westbrook Weaver to co-found Tempo Therapeutics.
Dr. Westbrook Weaver is highly experienced. He is a co-inventor of Tempo technology and a driving force behind the company's early development.He leads strategy and business development, as well as defines key pathways and heads corporate financing.Westbrook and Donald are alumni and good friends. Donald Griffin focuses on tissue engineering research, while he is dedicated to microfluidics. Although these two fields in bioengineering are usually independent of each other, their combination has given rise to an innovative technology—the Microscopic Angiogenic Particles (MAP) core technology, which became the foundation for the establishment of Tempo Therapeutics.
Donald GriffinDon is a co-inventor of MAP technology and a leading expert in the field of biomaterials and tissue engineering. He has over 14 years of experience as a researcher and professor of bioengineering and leads Tempo's scientific and new technology initiatives.
In 2015, the two published a research paper titled "Accelerated wound healing by injectable microporous gel scaffolds assembled from annealed building blocks" in Nature Materials, showcasing an injectable, interconnected microporous gel scaffold, which also serves as the technical cornerstone of the company. The study demonstrated that: in vitro, cells incorporated during the scaffold formation proliferated within 48 hours and formed an extensive three-dimensional network. In vivo, the scaffold promoted cell migration, achieving rapid skin tissue regeneration and tissue structure formation within five days. This material effectively avoided foreign body reactions while promoting regenerative immune responses and the rapid formation of vascularized tissue volume.
Tempo Therapeutics is developing new therapies based on MAP technology across many therapeutic areas. The company is actively engaged in establishing strategic relationships to support current developments and expand into new therapeutic fields, with the goal of leveraging tissue engineering to create a better life for patients in need.
More exciting content
Welcome to follow WeChat Video Channel
Johnson & Johnson Cuts 30% of Workforce in China, Is the "Giant" Accelerating Its Shift to Healthcare?
Hardcore Technology Leads the Vision, Lights Up the Metaverse
Medical Device Giant Completes Construction of Largest Overseas Production Base
FDA Announces: United Imaging Healthcare Tops in China Production
Just now, Medtronic issued another Level 1 recall
Orthopedic Giant: Leadership Change in Greater China
Top 100 Global Medical Device Companies 2024, Mindray Ranks 27th
Johnson & Johnson May Face $7.1 Billion in Damages Due to Surgical Robot
The King of Valves Begins Global Layoffs
BusinessBusiness cooperation email: qxzj@landianyiliao.com
